What is Zacks Research’s Estimate for HURA FY2026 Earnings?

TuHURA Biosciences, Inc. (NASDAQ:HURA) – Investment analysts at Zacks Research boosted their FY2026 EPS estimates for shares of TuHURA Biosciences in a research report issued to clients and investors on Thursday, April 9th. Zacks Research analyst J. Vandermosten now anticipates that the company will post earnings of ($0.48) per share for the year, up from their prior forecast of ($0.55). Zacks Research also issued estimates for TuHURA Biosciences’ FY2027 earnings at ($0.51) EPS.

TuHURA Biosciences (NASDAQ:HURA) last issued its quarterly earnings data on Tuesday, March 31st. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.01).

HURA has been the topic of several other research reports. Weiss Ratings reissued a “sell (e+)” rating on shares of TuHURA Biosciences in a research report on Thursday, January 22nd. HC Wainwright reissued a “buy” rating and set a $10.00 target price on shares of TuHURA Biosciences in a research report on Tuesday, February 3rd. Finally, Wall Street Zen raised shares of TuHURA Biosciences from a “sell” rating to a “hold” rating in a research report on Wednesday. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $9.00.

TuHURA Biosciences Trading Up 9.8%

NASDAQ:HURA opened at $3.15 on Tuesday. The company has a market cap of $200.28 million, a PE ratio of -5.00 and a beta of -0.32. TuHURA Biosciences has a twelve month low of $0.41 and a twelve month high of $4.44. The company’s 50 day moving average is $1.61 and its two-hundred day moving average is $1.60.

Institutional Trading of TuHURA Biosciences

Several institutional investors and hedge funds have recently bought and sold shares of HURA. Bank of America Corp DE acquired a new stake in TuHURA Biosciences during the 4th quarter valued at approximately $59,000. Jane Street Group LLC acquired a new stake in TuHURA Biosciences during the 1st quarter valued at approximately $69,000. Geode Capital Management LLC lifted its stake in TuHURA Biosciences by 111.4% during the 2nd quarter. Geode Capital Management LLC now owns 582,992 shares of the company’s stock valued at $1,300,000 after acquiring an additional 307,260 shares during the period. JPMorgan Chase & Co. acquired a new stake in TuHURA Biosciences during the 2nd quarter valued at approximately $27,000. Finally, New York State Common Retirement Fund acquired a new stake in TuHURA Biosciences during the 2nd quarter valued at approximately $97,000. 0.62% of the stock is currently owned by institutional investors and hedge funds.

TuHURA Biosciences News Summary

Here are the key news stories impacting TuHURA Biosciences this week:

• Positive Sentiment: Brookline Capital Markets sharply raised FY2026 and FY2027 EPS forecasts (FY2026 from ($0.59) to ($0.38); FY2027 from ($0.58) to ($0.36)) and also improved FY2028 to ($0.30) from ($0.44) — a material reduction in projected losses that likely underpins investor buying. Article Title
• Positive Sentiment: Zacks Research raised its FY2026 and FY2027 EPS estimates (FY2026 from ($0.55) to ($0.48); FY2027 from ($0.58) to ($0.51)), reinforcing the view that analyst expectations for future losses are moderating. Article Title
• Neutral Sentiment: Brookline published quarterly forecasts for 2026 showing ongoing negative EPS each quarter (Q1: ($0.10); Q2–Q4: ($0.09)), so while estimates improved year-over-year, the company is still expected to remain unprofitable near-term — a reminder this is a recovery/turnaround story rather than near-term profitability. Article Title

About TuHURA Biosciences

TuHURA Biosciences is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics using high‐dimensional proteomics. The company’s core mission is to translate complex protein signatures into actionable drug targets across a range of disease areas. By integrating proteomic data with advanced computational analytics, TuHURA aims to bridge the gap between molecular disease understanding and the development of first‐in‐class therapies.

At the heart of TuHURA’s approach is its proprietary platform, which leverages multiplexed protein profiling to generate rich phenotypic maps of disease states.